Characteristics of Bacilliq® SC /SporebioticTM SC


Bacillus subtilis HU58®

  • Produces Short Chain Fatty Acids (SCFA) - mainly butyrate, which has beneficial effects on the development of a healthy immune system and gut health.
  • Resporulation of B. subtilis HU58® plays a major role in the development of Gut Associated Lymphoid Tissue (GALT) which is important for both adaptive and innate immunity.
  • Several studies have shown the role of B. subtilis HU58® in treatment and prophylaxis of intestinal disorders in humans inclusive of antibiotic associated diarrhea & acute/chronic diarrhea.

 

Bacillus coagulans SC208®

  • Well documented to aid digestion and control symptoms such as abdominal pain, bloating, gas and diarrhea
  • Produces lactic acid , which creates a acidic environment preventing the growth of pathogenic microbes and promotes the growth of B. coagulans which ultimately dominate the microflora.
  • Possesses significant β-galactosidase (lactase) activity and lactic acid dehydrogenase activity, thereby enhancing the digestibility of lactose in patients with lactose intolerance.

Composition and dose of bottle/vial/capsule formulations


Benefits of Bacilliq® SC /SporebioticTM SC


Proven benefits in antibiotic associated diarrhea

  • An in vitro M-SHIME gut model study demonstrated that under condition of antibiotic induced dysbiosis, treatment with probiotic formulation of Bacillus coagulans SC208® and Bacillus subtilis HU58® has a beneficial effect on recovery of the microbial community. Additionally, the probiotic combination reduces gut membrane barrier damage and significantly decreases levels of pro-inflammatory markers compared with the no probiotic treatment.1

    Proven to resolve diarrhea

  • An open labelled, placebo-controlled trial conducted in a group of 75 patients suffering from antibiotic associated diarrhea proved the efficacy of Bacillus subtilis HU58® (dose 2 billion CFU) and Bacillus coagulans SC208® (dose 1 billion CFU) per capsule for 7 days. Additionally, symptoms as pain in abdomen, bloating and flatulence were also reduced.2
References

1. Marzorati M, Abbeele PV, Buyback SS, et al. Bacillus subtilis HU58 and Bacillus coagulans SC208 Probiotics Reduced the Effects of Antibiotic-Induced Gut Microbiome Dysbiosis in An M-SHIME® Model. Microorganisms. 2020;8(7): E1028.
2. Mehta DS, De Souza A, Jadhav SS, et al. An Open Labelled, Placebo Controlled Trial to Evaluate the Role of Probiotics- Bacillus subtilis HU58 and Bacillus coagulans SC208 on Antibiotic Associated Diarrhoea in Humans.2020 [Data on file].